Business Description
![Molecular Partners AG Molecular Partners AG logo](https://static.gurufocus.com/logos/0C0000AR9M.png?14)
Molecular Partners AG
ISIN : CH0256379097
Compare
Compare
Traded in other countries / regions
MOLN.SwitzerlandMOLN.USAMOLNz.UK6ML0.Germany IPO Date
2014-11-10Description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 51.96 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 5.68 | |||||
Beneish M-Score | 0.63 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -16.9 | |||||
3-Year EBITDA Growth Rate | 8.7 | |||||
3-Year EPS without NRI Growth Rate | 9.4 | |||||
3-Year FCF Growth Rate | -14.1 | |||||
3-Year Book Growth Rate | 13.4 | |||||
Future 3-5Y EPS without NRI Growth Rate | -8.38 | |||||
Future 3-5Y Total Revenue Growth Rate | 29.03 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 35.36 | |||||
9-Day RSI | 47.04 | |||||
14-Day RSI | 53.06 | |||||
6-1 Month Momentum % | -2.05 | |||||
12-1 Month Momentum % | -33.59 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 14.68 | |||||
Quick Ratio | 14.68 | |||||
Cash Ratio | 14.18 | |||||
Days Sales Outstanding | 92.41 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.1 | |||||
Shareholder Yield % | 0.59 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -919.98 | |||||
Net Margin % | -870.22 | |||||
FCF Margin % | -896.36 | |||||
ROE % | -30.19 | |||||
ROA % | -27.17 | |||||
ROIC % | -515.85 | |||||
ROC (Joel Greenblatt) % | -975.67 | |||||
ROCE % | -29.11 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 29.85 | |||||
PB Ratio | 1.19 | |||||
Price-to-Tangible-Book | 1.19 | |||||
EV-to-EBIT | -0.54 | |||||
EV-to-EBITDA | -0.56 | |||||
EV-to-Revenue | 4.65 | |||||
EV-to-FCF | -0.52 | |||||
Price-to-Projected-FCF | 3.6 | |||||
Price-to-Net-Current-Asset-Value | 1.23 | |||||
Price-to-Net-Cash | 1.28 | |||||
Earnings Yield (Greenblatt) % | -185.19 | |||||
FCF Yield % | -29.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Molecular Partners AG Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil CHF) | 6.726 | ||
EPS (TTM) (CHF) | -1.78 | ||
Beta | 0.14 | ||
Volatility % | 47.31 | ||
14-Day RSI | 53.06 | ||
14-Day ATR (CHF) | 0.633734 | ||
20-Day SMA (CHF) | 6.4585 | ||
12-1 Month Momentum % | -33.59 | ||
52-Week Range (CHF) | 3.1 - 9.49 | ||
Shares Outstanding (Mil) | 33.18 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Molecular Partners AG Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Molecular Partners AG Stock Events
Event | Date | Price(CHF) | ||
---|---|---|---|---|
No Event Data |
Molecular Partners AG Frequently Asked Questions
What is Molecular Partners AG(CHIX:MOLNz)'s stock price today?
The current price of CHIX:MOLNz is CHF6.08. The 52 week high of CHIX:MOLNz is CHF9.49 and 52 week low is CHF3.10.
When is next earnings date of Molecular Partners AG(CHIX:MOLNz)?
The next earnings date of Molecular Partners AG(CHIX:MOLNz) is 2024-08-26.
Does Molecular Partners AG(CHIX:MOLNz) pay dividends? If so, how much?
Molecular Partners AG(CHIX:MOLNz) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |